Anti-Therapeutic Action: infusion-related reactions

New Strategies to Combat Human Fungal Infections

mycolabadmin

Fungal infections are becoming a major global health threat, causing millions of deaths annually. This research collection presents new and improved ways to treat these infections, including natural compounds like chitosan, beneficial bacteria, new drug combinations, and tests to better understand which treatments work best. The papers showcase innovative approaches beyond traditional antifungal medications to help combat resistant infections.

Read More »

Efficacy of Rezafungin on Candida albicans Endophthalmitis in a Rabbit Model

mycolabadmin

Researchers tested a new antifungal medication called rezafungin to treat a serious eye infection caused by the fungus Candida albicans. Using rabbit models, they found that rezafungin was much more effective than two other antifungal drugs at clearing the infection from the eye and preventing damage to vision. The drug’s ability to work for longer periods with less frequent dosing makes it a promising candidate for treating this devastating infection in patients.

Read More »

Liposomal amphotericin B prophylaxis in paediatrics: a systematic review

mycolabadmin

This study reviews how a fungal medication called liposomal amphotericin B is used to prevent serious fungal infections in children with weakened immune systems, particularly those with blood cancers or who have had bone marrow transplants. The researchers found that this medicine prevents infections in about 93% of children, though it does cause side effects like low potassium levels in about 23% of patients. However, the study shows that current use of this medicine is quite varied and more high-quality research is needed to determine the best dosing approach.

Read More »
Scroll to Top